Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-Current Deferred Tax Liability: 2014-2017

Historic Non-Current Deferred Tax Liability for Vanda Pharmaceuticals (VNDA) over the last 4 years, with Dec 2017 value amounting to -$386,000.

  • Vanda Pharmaceuticals' Non-Current Deferred Tax Liability fell 157.96% to -$386,000 in Q4 2017 from the same period last year, while for Dec 2017 it was -$386,000, marking a year-over-year decrease of 157.96%. This contributed to the annual value of -$386,000 for FY2017, which is 157.96% down from last year.
  • As of FY2017, Vanda Pharmaceuticals' Non-Current Deferred Tax Liability stood at -$386,000, which was down 157.96% from $666,000 recorded in FY2016.
  • In the past 5 years, Vanda Pharmaceuticals' Non-Current Deferred Tax Liability ranged from a high of $1.1 million in FY2015 and a low of -$386,000 during FY2017.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $666,000 (2016), whereas its average is $460,000.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first surged by 18,233.33% in 2015, then plummeted by 157.96% in 2017.
  • Yearly analysis of 4 years shows Vanda Pharmaceuticals' Non-Current Deferred Tax Liability stood at $6,000 in 2014, then surged by 18,233.33% to $1.1 million in 2015, then plummeted by 39.45% to $666,000 in 2016, then slumped by 157.96% to -$386,000 in 2017.